TA50 Stock Overview
A biotechnology company, develops novel circular RNA and immunotherapy medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Circio Holding ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.04 |
| 52 Week High | NOK 0.90 |
| 52 Week Low | NOK 0.0002 |
| Beta | 1.61 |
| 11 Month Change | 6,566.67% |
| 3 Month Change | -60.00% |
| 1 Year Change | -93.44% |
| 33 Year Change | -99.66% |
| 5 Year Change | -99.72% |
| Change since IPO | -99.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| TA50 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.02% | -1.5% |
| 1Y | -93.4% | -17.7% | 7.9% |
Return vs Industry: TA50 underperformed the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: TA50 underperformed the German Market which returned 8.3% over the past year.
Price Volatility
| TA50 volatility | |
|---|---|
| TA50 Average Weekly Movement | 5,931.7% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TA50's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: TA50's weekly volatility has increased from 3067% to 5932% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 8 | Erik Wiklund | www.circio.com |
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023.
Circio Holding ASA Fundamentals Summary
| TA50 fundamental statistics | |
|---|---|
| Market cap | €2.10m |
| Earnings (TTM) | €812.91k |
| Revenue (TTM) | €10.53k |
2.6x
P/E Ratio199.4x
P/S RatioIs TA50 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TA50 income statement (TTM) | |
|---|---|
| Revenue | NOK 123.00k |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 123.00k |
| Other Expenses | -NOK 9.38m |
| Earnings | NOK 9.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.28 |
| Gross Margin | 100.00% |
| Net Profit Margin | 7,722.76% |
| Debt/Equity Ratio | -81.1% |
How did TA50 perform over the long term?
See historical performance and comparison